Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

NK/T Cell Lymphoma Nos Clinical Trial

Official title:
A Prospective Phase II Study of Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Patients With Newly Diagnosed Extra-nodal NK/T-cell Lymphoma

Status Recruiting

Clinical Trial Summary

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04484506
Study type	Interventional
Source	Peking University
Contact	Jun Zhu, Dr.
Phone	+86-13910333346
Email	zhu-jun@bjcancer.org
Status	Recruiting
Phase	Phase 2
Start date	October 20, 2011
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04127227` - Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type	Phase 2
Recruiting	`NCT04365036` - A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)	Phase 3
Not yet recruiting	`NCT05316246` - Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma	Phase 2
Recruiting	`NCT04231370` - Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma	Phase 2